These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12567413)

  • 1. Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk.
    Armstrong K; Weber B; Stopfer J; Calzone K; Putt M; Coyne J; Schwartz JS
    Am J Med Genet A; 2003 Mar; 117A(2):154-60. PubMed ID: 12567413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
    Armstrong K; Micco E; Carney A; Stopfer J; Putt M
    JAMA; 2005 Apr; 293(14):1729-36. PubMed ID: 15827311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interest in BRCA1/2 testing in a primary care population.
    Armstrong K; Weber B; Ubel PA; Guerra C; Schwartz JS
    Prev Med; 2002 Jun; 34(6):590-5. PubMed ID: 12052018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
    Hall MJ; Reid JE; Wenstrup RJ
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1579-85. PubMed ID: 21149333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subjective and objective risk of breast cancer in Ashkenazi Jewish individuals at risk for BRCA1/2 mutations.
    Kelly K; Leventhal H; Marvin M; Toppmeyer D; Much J; Dermody J; Baran J; Schwalb M
    Genet Test; 2004; 8(2):139-47. PubMed ID: 15345111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
    Hull LE; Haas JS; Simon SR
    Am J Prev Med; 2018 Feb; 54(2):221-228. PubMed ID: 29241717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.
    Levy DE; Byfield SD; Comstock CB; Garber JE; Syngal S; Crown WH; Shields AE
    Genet Med; 2011 Apr; 13(4):349-55. PubMed ID: 21358336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling.
    Høberg-Vetti H; Eide GE; Siglen E; Listøl W; Haavind MT; Hoogerbrugge N; Bjorvatn C
    Acta Oncol; 2019 Feb; 58(2):175-181. PubMed ID: 30334464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
    Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.
    Steffen LE; Du R; Gammon A; Mandelblatt JS; Kohlmann WK; Lee JH; Buys SS; Stroup AM; Campo RA; Flores KG; Vicuña B; Schwartz MD; Kinney AY
    Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1772-1780. PubMed ID: 28971986
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.
    Wevers MR; Schmidt MK; Engelhardt EG; Verhoef S; Hooning MJ; Kriege M; Seynaeve C; Collée M; van Asperen CJ; Tollenaar RA; Koppert LB; Witkamp AJ; Rutgers EJ; Aaronson NK; Rookus MA; Ausems MG
    Fam Cancer; 2015 Sep; 14(3):355-63. PubMed ID: 25700605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study.
    McCarthy AM; Bristol M; Fredricks T; Wilkins L; Roelfsema I; Liao K; Shea JA; Groeneveld P; Domchek SM; Armstrong K
    Cancer; 2013 Oct; 119(20):3596-603. PubMed ID: 23861169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population.
    McGuinness JE; Trivedi MS; Silverman T; Marte A; Mata J; Kukafka R; Crew KD
    Cancer Genet; 2019 Jun; 235-236():72-76. PubMed ID: 31078448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center.
    Shannon KM; Lubratovich ML; Finkelstein DM; Smith BL; Powell SN; Seiden MV
    Cancer; 2002 Jan; 94(2):305-13. PubMed ID: 11900216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer.
    Susswein LR; Skrzynia C; Lange LA; Booker JK; Graham ML; Evans JP
    J Clin Oncol; 2008 Jan; 26(1):32-6. PubMed ID: 18165638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.